- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-226/23 R: Order of the President of the General Court of 19 July 2023 — Neuraxpharm Pharmaceuticals v Commission (Interim relief — Medicinal products for human use — Marketing authorisation — Application for interim measures — Application for injunction — Lack of urgency)
ECLI:EU:UNKNOWN:62023TB0226
62023TB0226
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
25.9.2023
Official Journal of the European Union
C 338/24
(Case T-226/23 R)
(Interim relief - Medicinal products for human use - Marketing authorisation - Application for interim measures - Application for injunction - Lack of urgency)
(2023/C 338/32)
Language of the case: English
Parties
Applicant: Neuraxpharm Pharmaceuticals, SL (Barcelona, Spain) (represented by: K. Roox, T. De Meese, J. Stuyck, M. Van Nieuwenborgh and C. Dumont, lawyers)
Defendant: European Commission (represented by: E. Mathieu and C. Valero, acting as Agents)
Re:
By its application based on Articles 278 and 279 TFEU, the applicant seeks, in essence, first, suspension of operation of the decision of the European Commission contained in its letter of 17 March 2023, by which the Commission requires it to comply with the protection period for the reference medicinal product Tecfidera — Dimethyl fumarate as regards the placing on the market of the medicinal product Dimethyl fumarate Neuraxpharm — Dimethyl fumarate (‘DMF Neuraxpharm’) and to give written undertakings to that effect and any subsequent decision or act extending or replacing the contested measure, in so far as they concern it, and, second, an injunction requiring the Commission to refrain from taking any other measures which would amount to a withdrawal of the marketing authorisation enjoyed by it or a prohibition on placing DMF Neuraxpharm on the market.
Operative part of the order
1.The application for interim measures is dismissed.
2.The costs are reserved.